BioCentury | Jun 5, 2018
Company News

Zai Lab names Liang as first CCO

Zai Lab Ltd. (NASDAQ:ZLAB) announced William Liang has joined the Chinese biotech as its first chief commercial officer. Liang has over 20 years of experience running commercial operations for pharma in China. He was previously...
BioCentury | Apr 27, 2018
Company News

Zai gets Asia-Pacific license to Entasis' antibiotic combinations

Zai Lab Ltd. (NASDAQ:ZLAB) received an exclusive license to develop and commercialize ETX2514/sulbactam from Entasis Therapeutics Inc. (Waltham, Mass.) in the Asia-Pacific region. The candidate is in Phase II testing to treat severe Acinetobacter baumannii...
BioCentury | Jul 27, 2015
Clinical News

Solanezumab: Phase III data

Eli Lilly and researchers at the University of California San Diego reported data from a pre-specified secondary delayed-start analysis of pooled data from 1,322 patients with mild AD in the Phase III EXPEDITION, EXPEDITION2 and...
BioCentury | Jul 23, 2015
Clinical News

Lilly says solanezumab data suggest disease-modifying effect

Eli Lilly and Co. (NYSE:LLY) reported results from two Phase III studies and an extension study of solanezumab showing that patients with mild Alzheimer's disease (AD) who started treatment immediately retained a benefit in cognitive...
BioCentury | Jun 19, 2014
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Chemokine CC motif ligand 20 (CCL20; MIP3A) Mouse studies suggest the heparan sulfate-binding monosaccharide 2,4-O-disulfated iduronic acid (Di-S-IdoA) could help treat asthma. In a...
BioCentury | Aug 22, 2013
Targets & Mechanisms

Tamping down TAU

Despite evidence that pathologic TAU spreads through the brain in tauopathies such as Alzheimer's disease and frontotemporal dementia, the actual mechanism by which the misfolded protein propagates is murky. A key player in the process...
BioCentury | Aug 1, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) In vitro and cell culture studies identified a PfMDR1-targeting compound, ACT-213615, that...
BioCentury | Jul 15, 2013
Clinical News

Eliquis apixaban: Phase III data

The double-blind, international Phase III AMPLIFY trial in 5,395 patients with acute VTE - symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) - showed that twice-daily oral Eliquis for 6 months met the primary endpoint of...
BioCentury | Jul 2, 2013
Clinical News

Eliquis meets in Phase III for acute VTE

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) said twice-daily oral Eliquis apixaban for six months met the primary endpoint of non-inferiority to conventional therapy consisting of subcutaneous enoxaparin followed by warfarin in the...
BioCentury | Dec 17, 2012
Clinical News

Eliquis apixaban: Phase III data

The double-blind, international Phase III AMPLIFY-EXT trial in 2,486 patients with VTE who completed 6-12 months of prior anticoagulation therapy showed that twice-daily 2.5 and 5 mg Eliquis for 1 year each met the composite...
Items per page:
1 - 10 of 21